Perimenopausal women gain weight that may alter inflammatory status, endocrine equilibrium, and the intensity of vasomotor symptoms.
To measure serum levels of markers related to adiposity, inflammation/angiogenesis and digestive metabolism and correlate them with body mass index (BMI), waist-to-hip ratio (WHR), metabolic parameters and menopausal symptoms (assessed with the 10-item Cervantes Scale [CS-10]).
Serum of perimenopausal women (n = 24), STRAW stages-2 and -1, was analyzed using the Bio-Plex 200 System technology to assess 30 proposed analytes. The MetS was defined by the American Heart Association criteria and women were divided as: normal BMI (NBMI), excessive BMI (EBMI), and EBMI with MetS (EBMI–MetS).
Weight, BMI, abdominal circumference, WHR, systolic blood pressure, glucose and triglyceride levels were significantly higher and high-density lipoprotein cholesterol (HDL-C) was lower in EBMI-MetS women compared to NBMI ones. Insulin, C-peptide, resistin, adipsin, GIP, leptin, IL-6, FGF21 and PAI-1 levels were significantly higher and ghrelin and IGFBP-1 lower in EBMI–MetS women as compared to NBMI ones. Spearman’s correlation of pooled data showed a significant positive correlation between abdominal perimeter and WHR and C-peptide, insulin, adipsin, resistin, leptin, PAI-1 and FGF21 and a negative correlation with IGFBP-1 levels. Total CS-10 scores and hot flush intensity did not differ between studied groups, yet positively correlated with anthropometric values but not with studied analytes.
Perimenopausal women with EBMI and the MetS showed an altered metabolic profile, but no differences in menopausal symptoms which also did not correlate with changes in studied biomarkers.
This is a preview of subscription content, log in to check access.
Buy single article
Instant unlimited access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
10-item Cervantes Scale
Body mass index
Excessive body mass index
Fibroblast growth factor 21
Fibroblast growth factor 23
Glucose-dependent insulinotropic peptide
High-density lipoprotein cholesterol
Homeostatic model assessment
Insulin growth factor-binding protein 1
Low-density lipoprotein cholesterol
Normal body mass index
Obstructive sleep apneas
Plasminogen activator inhibitor-1
Soluble Fas ligand
Soluble form of cluster of differentiation 40 ligand
Soluble leptin receptor
Stages of Reproductive Aging Workshop
Tumor necrosis factor alpha
Urokinase-type plasminogen activator
Vascular endothelial growth factor A
World Health Organization
Stevenson JC, Tsiligiannis S, Panay N (2018) Cardiovascular risk in perimenopausal women. Curr Vasc Pharmacol. https://doi.org/10.2174/1570161116666181002145340
Janssen I, Powell LH, Crawford S et al (2008) Menopause and the metabolic syndrome: the Study of Women’s Health Across the Nation. Arch Intern Med 168:1568–1575. https://doi.org/10.1001/archinte.168.14.1568
Gurka MJ, Vishnu A, Santen RJ, DeBoer MD (2016) Progression of metabolic syndrome severity during the menopausal transition. J Am Hear Assoc. https://doi.org/10.1161/JAHA.116.003609
Davis SR, Castelo-Branco C, Chedraui P et al (2012) Understanding weight gain at menopause. Climacteric 15:419–429. https://doi.org/10.3109/13697137.2012.707385
da Alexandre ST, Aubertin-Leheudre M, Carvalho LP et al (2018) Dynapenic obesity as an associated factor to lipid and glucose metabolism disorders and metabolic syndrome in older adults—findings from SABE Study. Clin Nutr 37:1360–1366. https://doi.org/10.1016/j.clnu.2017.06.009
Garcia-Alfaro P, Garcia S, Rodriguez I et al (2019) Factors related to muscle strength in postmenopausal women aged younger than 65 years with normal vitamin D status. Climacteric. https://doi.org/10.1080/13697137.2018.1554645
Perez-Lopez FR, Chedraui P (2017) The metabolic syndrome in mid-aged women. In: Cano A (ed) Menopause: a comprehensive approach. Springer Nature, Cham, pp 141–151
Pérez-López FR, Larrad-Mur L, Kallen A et al (2010) Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 17:511–531. https://doi.org/10.1177/1933719110367829
Chedraui P, Perez-Lopez FR (2019) Metabolic syndrome during female midlife: what are the risks? Climacteric 22:127–132. https://doi.org/10.1080/13697137.2018.1561666
Tilg H, Moschen AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6:772–783. https://doi.org/10.1038/nri1937
Chedraui P, Escobar GS, Pérez-López FR et al (2014) Angiogenesis, inflammation and endothelial function in postmenopausal women screened for the metabolic syndrome. Maturitas. https://doi.org/10.1016/j.maturitas.2014.01.014
Chedraui P, Pérez-López FR, Escobar GS et al (2014) Circulating leptin, resistin, adiponectin, visfatin, adipsin and ghrelin levels and insulin resistance in postmenopausal women with and without the metabolic syndrome. Maturitas. https://doi.org/10.1016/j.maturitas.2014.06.008
Hameed S, Dhillo WS, Bloom SR (2009) Gut hormones and appetite control. Oral Dis 15:18–26. https://doi.org/10.1111/j.1601-0825.2008.01492.x
El-Salhy M, Mazzawi T, Hausken T, Hatlebakk JG (2016) Interaction between diet and gastrointestinal endocrine cells. Biomed Rep 4:651–656. https://doi.org/10.3892/br.2016.649
Cagnacci A, Palma F, Romani C et al (2015) Are climacteric complaints associated with risk factors of cardiovascular disease in peri-menopausal women? Gynecol Endocrinol 31:359–362. https://doi.org/10.3109/09513590.2014.998188
Franco OH, Muka T, Colpani V et al (2015) Vasomotor symptoms in women and cardiovascular risk markers: systematic review and meta-analysis. Maturitas 81:353–361. https://doi.org/10.1016/j.maturitas.2015.04.016
Tuomikoski P, Savolainen-Peltonen H (2017) Vasomotor symptoms and metabolic syndrome. Maturitas 97:61–65. https://doi.org/10.1016/j.maturitas.2016.12.010
Thurston RC, El Khoudary SR, Sutton-Tyrrell K et al (2012) Vasomotor symptoms and insulin resistance in the study of women’s health across the nation. J Clin Endocrinol Metab 97:3487–3494. https://doi.org/10.1210/jc.2012-1410
van Dijk GM, Maneva M, Colpani V et al (2015) The association between vasomotor symptoms and metabolic health in peri- and postmenopausal women: a systematic review. Maturitas 80:140–147. https://doi.org/10.1016/j.maturitas.2014.11.016
Harlow SD, Gass M, Hall JE et al (2012) Executive summary of the stages of reproductive aging workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 97:1159–1168. https://doi.org/10.1210/jc.2011-3362
World Health Organization (2019) BMI classification. http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle/body-mass-index-bmi. Accessed Nov 2019
Perez-Lopez FR, Fernandez-Alonso AM, Perez-Roncero G et al (2013) Assessment of menopause-related symptoms in mid-aged women with the 10-item Cervantes Scale. Maturitas 76:151–154. https://doi.org/10.1016/j.maturitas.2013.07.002
Chedraui P, Perez-Lopez FR, Sanchez H et al (2014) Application of the 10-item Cervantes Scale among mid-aged Ecuadorian women for the assessment of menopausal symptoms. Maturitas 79:100–105. https://doi.org/10.1016/j.maturitas.2014.06.019
Grundy SM, Cleeman JI, Daniels SR et al (2005) Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 112:2735–2752. https://doi.org/10.1161/CIRCULATIONAHA.105.169404
Chedraui P, San Miguel G, Villacreses D et al (2013) Assessment of insomnia and related risk factors in postmenopausal women screened for the metabolic syndrome. Maturitas 74:154–159. https://doi.org/10.1016/j.maturitas.2012.10.017
Houser B (2012) Bio-Rad’s Bio-Plex(R) suspension array system, xMAP technology overview. Arch Physiol Biochem 118:192–196. https://doi.org/10.3109/13813455.2012.705301
Dodds RM, Syddall HE, Cooper R et al (2014) Grip strength across the life course: normative data from twelve British studies. PLoS One 9:e113637. https://doi.org/10.1371/journal.pone.0113637
Lovejoy JC, Champagne CM, de Jonge L et al (2008) Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes (Lond) 32:949–958. https://doi.org/10.1038/ijo.2008.25
Marlatt KL, Redman LM, Beyl RA et al (2019) Racial differences in body composition and cardiometabolic risk during the menopause transition: a prospective, observational cohort study. Am J Obstet Gynecol. https://doi.org/10.1016/j.ajog.2019.09.051
Abildgaard J, Danielsen ER, Dorph E et al (2018) Ectopic lipid deposition is associated with insulin resistance in postmenopausal women. J Clin Endocrinol Metab 103:3394–3404. https://doi.org/10.1210/jc.2018-00554
Bueno-Notivol J, Calvo-Latorre J, Alonso-Ventura V et al (2017) Effect of programmed exercise on insulin sensitivity in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Menopause 24:1404–1413. https://doi.org/10.1097/GME.0000000000000936
Lee CG, Carr MC, Murdoch SJ et al (2009) Adipokines, inflammation, and visceral adiposity across the menopausal transition: a prospective study. J Clin Endocrinol Metab 94:1104–1110. https://doi.org/10.1210/jc.2008-0701
Tamakoshi K, Yatsuya H, Wada K et al (2007) The transition to menopause reinforces adiponectin production and its contribution to improvement of insulin-resistant state. Clin Endocrinol 66:65–71. https://doi.org/10.1111/j.1365-2265.2006.02687.x
Ben Ali S, Jemaa R, Ftouhi B et al (2011) Relationship of plasma leptin and adiponectin concentrations with menopausal status in Tunisian women. Cytokine 56:338–342. https://doi.org/10.1016/j.cyto.2011.06.026
Mostafazadeh M, Haiaty S, Rastqar A, Keshvari M (2018) Correlation between resistin level and metabolic syndrome component: a review. Horm Metab Res 50:521–536. https://doi.org/10.1055/a-0637-1975
Park HT, Cho SH, Cho GJ et al (2009) Relationship between serum adipocytokine levels and metabolic syndrome in menopausal women. Gynecol Endocrinol 25:27–31. https://doi.org/10.1080/09513590802404021
Sowers MR, Wildman RP, Mancuso P et al (2008) Change in adipocytokines and ghrelin with menopause. Maturitas 59:149–157. https://doi.org/10.1016/j.maturitas.2007.12.006
Chu S, Ding W, Li K et al (2008) Plasma resistin associated with myocardium injury in patients with acute coronary syndrome. Circ J 72:1249–1253. https://doi.org/10.1253/circj.72.1249
White RT, Damm D, Hancock N et al (1992) Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue. J Biol Chem 267:9210–9213
Lo JC, Ljubicic S, Leibiger B et al (2014) Adipsin is an adipokine that improves beta cell function in diabetes. Cell 158:41–53. https://doi.org/10.1016/j.cell.2014.06.005
Napolitano A, Lowell BB, Damm D et al (1994) Concentrations of adipsin in blood and rates of adipsin secretion by adipose tissue in humans with normal, elevated and diminished adipose tissue mass. Int J Obes Relat Metab Disord 18:213–218
Schrover IM, van der Graaf Y, Spiering W et al (2018) The relation between body fat distribution, plasma concentrations of adipokines and the metabolic syndrome in patients with clinically manifest vascular disease. Eur J Prev Cardiol 25:1548–1557. https://doi.org/10.1177/2047487318790722
Nieuwdorp M, Stroes ES, Meijers JC, Buller H (2005) Hypercoagulability in the metabolic syndrome. Curr Opin Pharmacol 5:155–159. https://doi.org/10.1016/j.coph.2004.10.003
Mertens I, Verrijken A, Michiels JJ et al (2006) Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes 30:1308–1314. https://doi.org/10.1038/sj.ijo.0803189
Dandona P, Aljada A, Bandyopadhyay A (2004) Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol 25:4–7
Zhang X, Yeung DC, Karpisek M et al (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246–1253. https://doi.org/10.2337/db07-1476
Muller TD, Nogueiras R, Andermann ML et al (2015) Ghrelin. Mol Metab 4:437–460. https://doi.org/10.1016/j.molmet.2015.03.005
Poykko SM, Kellokoski E, Horkko S et al (2003) Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52:2546–2553. https://doi.org/10.2337/diabetes.52.10.2546
Barazzoni R, Zanetti M, Ferreira C et al (2007) Relationships between desacylated and acylated ghrelin and insulin sensitivity in the metabolic syndrome. J Clin Endocrinol Metab 92:3935–3940. https://doi.org/10.1210/jc.2006-2527
Tschop M, Weyer C, Tataranni PA et al (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50:707–709
Shiiya T, Nakazato M, Mizuta M et al (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87:240–244. https://doi.org/10.1210/jcem.87.1.8129
Ukkola O (2005) Ghrelin and the metabolic balance. J Endocrinol Investig 28:849–852
Reinehr T, Kleber M, Toschke AM et al (2011) Longitudinal association between IGFBP-1 levels and parameters of the metabolic syndrome in obese children before and after weight loss. Int J Pediatr Obes 6:236–243. https://doi.org/10.3109/17477166.2010.544739
Lewitt MS, Hilding A, Brismar K et al (2010) IGF-binding protein 1 and abdominal obesity in the development of type 2 diabetes in women. Eur J Endocrinol 163:233–242. https://doi.org/10.1530/EJE-10-0301
Muka T, Oliver-Williams C, Colpani V et al (2016) Association of vasomotor and other menopausal symptoms with risk of cardiovascular disease: a systematic review and meta-analysis. PLoS One 11:e0157417. https://doi.org/10.1371/journal.pone.0157417
Biglia N, Cagnacci A, Gambacciani M et al (2017) Vasomotor symptoms in menopause: a biomarker of cardiovascular disease risk and other chronic diseases? Climacteric 20:306–312. https://doi.org/10.1080/13697137.2017.1315089
Yasui T, Uemura H, Tomita J et al (2006) Association of interleukin-8 with hot flashes in premenopausal, perimenopausal, and postmenopausal women and bilateral oophorectomized women. J Clin Endocrinol Metab 91:4805–4808. https://doi.org/10.1210/jc.2006-1100
Alexander C, Cochran CJ, Gallicchio L et al (2010) Serum leptin levels, hormone levels, and hot flashes in midlife women. Fertil Steril 94:1037–1043. https://doi.org/10.1016/j.fertnstert.2009.04.001
Thurston RC, Chang Y, Mancuso P, Matthews KA (2013) Adipokines, adiposity, and vasomotor symptoms during the menopause transition: findings from the Study of Women’s Health Across the Nation. Fertil Steril 100:793–800. https://doi.org/10.1016/j.fertnstert.2013.05.005
Huang WY, Chang CC, Chen DR et al (2017) Circulating leptin and adiponectin are associated with insulin resistance in healthy postmenopausal women with hot flashes. PLoS One 12:e0176430. https://doi.org/10.1371/journal.pone.0176430
Jequier E (2002) Leptin signaling, adiposity, and energy balance. Ann N Y Acad Sci 967:379–388. https://doi.org/10.1111/j.1749-6632.2002.tb04293.x
Almabrouk TA, Ewart MA, Salt IP, Kennedy S (2014) Perivascular fat, AMP-activated protein kinase and vascular diseases. Br J Pharmacol 171:595–617. https://doi.org/10.1111/bph.12479
Gao CC, Kapoor E, Lipford MC et al (2018) Association of vasomotor symptoms and sleep apnea risk in midlife women. Menopause 25:391–398. https://doi.org/10.1097/GME.0000000000001020
Hitchcock CL, Elliott TG, Norman EG et al (2012) Hot flushes and night sweats differ in associations with cardiovascular markers in healthy early postmenopausal women. Menopause 19:1208–1214. https://doi.org/10.1097/gme.0b013e31825541cc
Tuomikoski P, Haapalahti P, Ylikorkala O, Mikkola TS (2010) Vasomotor hot flushes and 24-hour ambulatory blood pressure in recently post-menopausal women. Ann Med 42:216–222. https://doi.org/10.3109/07853891003657319
Yiannikouris F, Gupte M, Putnam K, Cassis L (2010) Adipokines and blood pressure control. Curr Opin Nephrol Hypertens 19:195–200. https://doi.org/10.1097/MNH.0b013e3283366cd0
We thank women who participated in the “The Omega II, Women’s Health Project: Evaluación de severidad de síntomas menopaúsicos, estado metabólico y depresión en mujeres de mediana edad”.
This research was partially supported by the Sistema de Investigación y Desarrollo and the Vice-Rectorado de Investigación & Postgrado of the Universidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador, through Grant no. SIU-318-853-2014 (The Omega II, Women’s Health Project 2014) provided to Peter Chedraui and Grant no. SIU-411-11-2017 provided to Isabel Grijalva-Grijalva; and also by VitaNova project, Grant CUP D18C15000130008, University of Pisa, Pisa Italy provided to Tommaso Simoncini.
Conflict of interest
All the authors declare that there are no conflicts of interest regarding the publication of this paper.
The research protocol was reviewed and approved by the Ethics and Bioethics Committee of the Enrique C. Sotomayor Hospital. All procedures performed in the present study involving humans were in accordance with the ethical standards of the institution or practice at which the studies were conducted. This article does not contain any studies with animals performed by any of the authors.
All study participants were informed about the research, its purposes and requested to provide written consent of participation.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Palla, G., Ramírez-Morán, C., Montt-Guevara, M.M. et al. Perimenopause, body fat, metabolism and menopausal symptoms in relation to serum markers of adiposity, inflammation and digestive metabolism. J Endocrinol Invest (2020). https://doi.org/10.1007/s40618-019-01168-6
- Metabolic syndrome
- Excessive body weight
- Digestive metabolism
- Menopausal symptoms
- Cervantes Scale